Abstract
G protein-coupled receptor 124 (GPR124; also called tumor endothelial marker 5, TEM5) is highly expressed in tumor vasculature. While recent studies have revealed a role in vasculogenesis, evidence for GPR124 function in tumor angiogenesis is lacking. Here, we demonstrate that GPR124 is required for VEGFinduced tumor angiogenesis. GPR124 silencing in human endothelial cells inhibited mouse xenograft tumor angiogenic vessel formation and tumor growth. GPR124 regulated VEGF-induced tumor angiogenic processes in vitro including cell-cell interaction, permeability, migration, invasion, and tube formation. Therefore, GPR124 plays a key role in VEGF-induced tumor angiogenesis.
Keywords: Angiogenesis, cancer, G protein coupled receptors (GPCR), tumor, vascular biology, vascular endothelial growth factor (VEGF).
Current Molecular Medicine
Title:G-Protein Coupled Receptor 124 (GPR124) in Endothelial Cells Regulates Vascular Endothelial Growth Factor (VEGF)-Induced Tumor Angiogenesis
Volume: 14 Issue: 4
Author(s): Y. Wang, S.-G. Cho, X. Wu, S. Siwko and M. Liu
Affiliation:
Keywords: Angiogenesis, cancer, G protein coupled receptors (GPCR), tumor, vascular biology, vascular endothelial growth factor (VEGF).
Abstract: G protein-coupled receptor 124 (GPR124; also called tumor endothelial marker 5, TEM5) is highly expressed in tumor vasculature. While recent studies have revealed a role in vasculogenesis, evidence for GPR124 function in tumor angiogenesis is lacking. Here, we demonstrate that GPR124 is required for VEGFinduced tumor angiogenesis. GPR124 silencing in human endothelial cells inhibited mouse xenograft tumor angiogenic vessel formation and tumor growth. GPR124 regulated VEGF-induced tumor angiogenic processes in vitro including cell-cell interaction, permeability, migration, invasion, and tube formation. Therefore, GPR124 plays a key role in VEGF-induced tumor angiogenesis.
Export Options
About this article
Cite this article as:
Wang Y., Cho S.-G., Wu X., Siwko S. and Liu M., G-Protein Coupled Receptor 124 (GPR124) in Endothelial Cells Regulates Vascular Endothelial Growth Factor (VEGF)-Induced Tumor Angiogenesis, Current Molecular Medicine 2014; 14 (4) . https://dx.doi.org/10.2174/1566524014666140414205943
| DOI https://dx.doi.org/10.2174/1566524014666140414205943 |
Print ISSN 1566-5240 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
From Molecular Mechanisms to Therapeutic Frontiers: The Versatile Roles of Chaperones in Medicine
Chaperones play critical roles in maintaining proteostasis by preventing protein misfolding and aggregation, which constitute central processes to the pathogenesis of numerous diseases such as neurodegeneration, cancer, and inflammatory disorders. This thematic issue will delve into the molecular mechanisms of chaperone function, their involvement in disease progression, and their potential ...read more
Metabolic Reprogramming and Molecular Pharmacology: Innovations in Drug Discovery and Therapeutic Targeting
Metabolic reprogramming is a hallmark of numerous diseases, including cancer, metabolic disorders, and neurodegeneration. Understanding the intricate cell signaling pathways, transduction pathways, and omics-based data is important for the development of novel pharmacological interventions. This special issue of Current Molecular Medicine will be devoted to the current advances in drug ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Approaches for the Inhibition of Human Telomerase Based on the Use of Peptide Nucleic Acids and Hammerhead Ribozymes
Mini-Reviews in Medicinal Chemistry Epidermal Growth Factor Receptors: A Functional Perspective
Current Radiopharmaceuticals Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Potential and Perspectives of Cyclonucleosides
Current Medicinal Chemistry Recent Patents Relating to Tumor Suppressor Genes
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: Genomic Applications to Various Biological Questions)
Current Genomics Inhibition of Aromatase (AR) by Benzyl Azole-Based Compounds
Letters in Drug Design & Discovery Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets Recent Advances in the Selection of Cancer-Specific Aptamers for the Development of Biosensors
Current Medicinal Chemistry PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders
Current Drug Delivery Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Decision Support System for Lymphoma Classification
Current Medical Imaging Development and Challenges of Cyclic Peptides for Immunomodulation
Current Protein & Peptide Science Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Therapeutic Nanoparticles and Associated Toxicity
Current Nanoscience Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent
Current Cancer Drug Targets





